Hospital Pharmacy Europe - Central nervous system,

Click here

Tuesday 21 May 2013 Register Login

You are here:

Suppliers Guide

New neurology product

Hospital Pharmacy Europe is assisting with a survey on messaging for a new neurology product. Click here

LATEST ISSUE

Contamination control and preparation of anticancer drugs, medicines reconciliation, Ruconest drug evaluation, ivacaftor for cystic fibrosis , oxycodone-naloxone prolonged-release tablets, IV chemotherapy, capsaicin in the treatment of severe neuropathic pain, alitretinoin in severe chronic hand eczema, Zyclara for actinic keratoses

Pharmacy Zone: Central nervous system

Magazine	Sponsored content
News	Video

Wed 17 Oct
2012

Rufinamide in Lennox-Gastaut syndrome
Rufinamide is an anti-epileptic drug that received marketing authorisation as adjunctive therapy in Lennox-Gastaut syndrome (LGS)...

Wed 22 Aug
2012

MRI findings dispute blood flow and MS correlation
While researchers have speculated that changes in brain blood flow due to vein abnormalities contribute to multiple sclerosis...

Thu 6 Oct
2011

CHMP recommends Xarelto® for DVT and stroke prevention
Bayer’s Xarelto® (rivaroxaban) recommended by CHMP for EU approval

Mon 18 Jul
2011

Trastuzumab improves survival in HER2-positive metastases
Study shows benefits of trastuzumab and chemotherapy in HER2-positive metastatic breast cancer patients

Wed 6 Jul
2011

New microarray test for cystic fibrosis detection
New technology-based test for cystic fibrosis is in Astra Biotech GmbH’s pre-launch phase

Thu 30 Jun
2011

Merck applies for Rebif extension in Europe
Global pharmaceutical company submits application to EMA.

Fri 10 Jun
2011

New restless legs syndrome treatment analysed
New post hoc analyses examined the effects on daytime functioning, daytime symptoms, pain RLS

Thu 9 Jun
2011

Study examined effects of Neupro in Parkinson’s disease
Post hoc analysis from RECOVER study examined effects on surrogate markers of mood and anhedonia

Wed 8 Jun
2011

First cannabis-based medicine approved in Denmark
Sativex® approved in Denmark for the treatment of spasticity due to Multiple Sclerosis (MS)

Thu 2 Jun
2011

Difficulties in diagnosing dementia type
Swedish study shows many patients receive wrong dementia diagnosis

Wed 1 Jun
2011

Lundbeck data updated
Update on Lundbeck's total number of voting rights and total share capital

Thu 26 May
2011

Treatment of spasticity due to MS approved in Germany
Launch of Sativex® in Germany is expected in July 2011

Mon 23 May
2011

MS Society unveils world-first Register at start of MS Week
New initiative during MS Week could give first true picture of MS in the UK

Web design, hosting and programming by ModeZero